

Vincenzo Serretta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7816295/publications.pdf>

Version: 2024-02-01

40
papers

955
citations

686830

13
h-index

454577

30
g-index

41
all docs

41
docs citations

41
times ranked

1477
citing authors

#	ARTICLE	IF	CITATIONS
1	Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: a contemporary series of 1800 interventions. <i>Urology</i> , 2002, 60, 623-627.	0.5	203
2	Prognostic Factors and Risk Groups in T1G3 Non-muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. <i>European Urology</i> , 2015, 67, 74-82.	0.9	190
3	An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 507-514.	1.2	77
4	Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. <i>European Urology Oncology</i> , 2018, 1, 403-410.	2.6	66
5	The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 484.e19-484.e25.	0.8	53
6	Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. <i>Urology</i> , 2005, 65, 65-69.	0.5	45
7	Concordance and Clinical Significance of Uncommon Variants of Bladder Urothelial Carcinoma in Transurethral Resection and Radical Cystectomy Specimens. <i>Urology</i> , 2014, 84, 1141-1146.	0.5	42
8	TUR and Adjuvant Intravesical Chemotherapy in T1G3 Bladder Tumors: Recurrence, Progression and Survival in 137 Selected Patients Followed Up to 20 Years. <i>European Urology</i> , 2004, 45, 730-736.	0.9	33
9	A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer. <i>BJU International</i> , 2010, 106, 212-217.	1.3	28
10	Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?. <i>Urologia Internationalis</i> , 2016, 96, 20-24.	0.6	22
11	A Randomized Trial Comparing Tamoxifen Therapy vs. Tamoxifen Prophylaxis in Bicalutamide-Induced Gynecomastia. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 174-179.	0.9	18
12	Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Non-muscle-invasive Bladder Carcinoma. <i>Urology</i> , 2013, 81, 277-282.	0.5	17
13	Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes. <i>Cancer Management and Research</i> , 2018, Volume 10, 5053-5060.	0.9	16
14	Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e751-e758.	0.9	12
15	Acute and late toxicity and preliminary outcomes report of moderately hypofractionated helical tomotherapy for localized prostate cancer: a mono-institutional analysis. <i>Radiologia Medica</i> , 2020, 125, 220-227.	4.7	12
16	Virtual Clinical and Precision Medicine Tumor Boards' Cloud-Based Platform-Mediated Implementation of Multidisciplinary Reviews Among Oncology Centers in the COVID-19 Era: Protocol for an Observational Study. <i>JMIR Research Protocols</i> , 2021, 10, e26220.	0.5	12
17	Correlation between GP-170 expression, prognosis, and chemoresistance of superficial bladder carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2003, 129, 472-476.	1.2	9
18	Multiplicity and History Have a Detrimental Effect on Survival of Patients With T1G3 Bladder Tumors Selected for Conservative Treatment. <i>Journal of Urology</i> , 2008, 180, 886-891.	0.2	9

#	ARTICLE	IF	CITATIONS
19	Characterization of human infiltrating and circulating gamma-delta T cells in prostate cancer. <i>Investigative and Clinical Urology</i> , 2019, 60, 91.	1.0	9
20	Segmental resection of distal ureter with terminoà€terminal ureteric anastomosis vs bladder cuff removal and ureteric reà€implantation for upper tract urothelial carcinoma: results of a multicentre study. <i>BJU International</i> , 2019, 124, 116-123.	1.3	8
21	Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study. <i>Urologia Internationalis</i> , 2020, 104, 396-401.	0.6	8
22	Is Kelami's Method Still Useful in the Smartphone Era? The Virtual 3-Dimensional Reconstruction of Penile Curvature in Patients With Peyronie's Disease: A Pilot Study. <i>Journal of Sexual Medicine</i> , 2021, 18, 209-214.	0.3	7
23	Cigarette Smoking and Drinking Water Source: Correlation with Clinical Features and Pathology of Superficial Bladder Carcinoma. <i>Urologia Internationalis</i> , 2009, 82, 318-323.	0.6	6
24	Mitomycin C from Birth to Adulthood. <i>Urologia</i> , 2016, 83, 2-6.	0.3	6
25	The Clinical Value of PSA Increase during Intravesical Adjuvant Therapy for Nonmuscle-Invasive Bladder Cancer. <i>Urologia</i> , 2016, 83, 145-148.	0.3	6
26	Segmental ureterectomy vs. radical nephroureterectomy for ureteral carcinoma in patients with a preoperative glomerular filtration rate less than 90 ml/min/1.73 m ² : A multicenter study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 601.e11-601.e16.	0.8	6
27	Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital. <i>Urologia Internationalis</i> , 2009, 83, 452-457.	0.6	5
28	Management of Symptomatic Benign Prostatic Hyperplasia in Southern Italy: A Retrospective Analysis of the Sicilian-Calabrian Society of Urology (SSCU) of 32,000 Patients. <i>Urologia Internationalis</i> , 2003, 71, 16-21.	0.6	4
29	Sildenafil orodispersible film in the treatment of erectile dysfunction after radical prostatectomy: A singleà€centre openà€label uncontrolled trial. <i>Andrologia</i> , 2020, 52, e13705.	1.0	4
30	Can We Clinically Distinguish Anejaculation From Retrograde Ejaculation in Patients on ð±1A-Blockers Therapy for Lower Urinary Tract Symptoms?. <i>Urology</i> , 2020, 139, 129-133.	0.5	4
31	Clinical implications of a rare renal entity: Pleomorphic Hyalinizing Angiectatic Tumor (PHAT). <i>Pathology Research and Practice</i> , 2017, 213, 165-169.	1.0	3
32	A prospective observational study on oral administration of Ellagic Acid and <i>Annona Muricata</i> in patients affected by non-muscle invasive bladder cancer not undergoing maintenance after 6-week intravesical prophylaxis. <i>Urologia</i> , 2022, 89, 49-52.	0.3	3
33	Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722199568.	0.9	3
34	Clinical Pitfalls in Diagnosis of Nonmuscle-Invasive Bladder Cancer. <i>Urologia</i> , 2015, 82, S1-S4.	0.3	2
35	Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 964-969.	0.8	2
36	Sexual dysfunction in dialytic patients. A prospective cross-sectional observational study in two hemodialysis centers. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 215-220.	0.4	2

#	ARTICLE	IF	CITATIONS
37	Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy. <i>Urology Annals</i> , 2015, 7, 21.	0.3	1
38	Although rare, severe complications following intravesical bacillus Calmette-Guerin treatment should not be overlooked!. <i>Infectious Diseases</i> , 2015, 47, 732-733.	1.4	1
39	Editorial Comment to Infectious aortic aneurysms occurring 1 year after bacillus Calmette-Guérin bladder instillation therapy. <i>International Journal of Urology</i> , 2015, 22, 235-236.	0.5	0
40	Time to safely omit bladder cuff removal for low-risk upper tract urothelial carcinoma. <i>Minerva Urology and Nephrology</i> , 2021, 73, 417-420.	1.3	0